Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2021 Apr 1.

Published in final edited form as: J Cancer Surviv. 2020 Jan 13;14(2):226–234. doi: 10.1007/s11764-019-00815-4

Table 2:

Study 2 sample demographics at baseline

		PPI Users (n = 31)			PPI Non-users (n = 169)

Measure		N (%)	M (SD)	N (%)	M (SD)
Age			54.4(9.9)		51.1(9.0)
Comorbidities			0.3(0.7)		0.1(0.4)
Months since cancer tx			14.0(8.6)^*		10.3(7.7)^*
Race (% White)		28(90%)		148(88%)
Education	High School	2(6%)		10(6%)
	Some College	7(23%)		42(25%)
	College Grad	9(29%)		53(31%)
	Grad Training	13(42%)		64(38%)
Chemo tx (% Yes)		15(48%)		107(54%)
Yoga group (% Yes)		17(55%)		83(49%)
Hormone tx (% Yes)		9(29%)		67(40%)
Radiation tx (% Yes)		23(74%)		105(62%)
CES-D score			9.0(6.3)		11.0(8.5)
Cancer Stage
	Stage 0	5(16%)		13(11%)
	Stage I	13(42%)		76(45%)
	Stage II	10(32%)		65(38%)
	Stage III	3(10%)		15(9%)

^*

p<0.05